[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340946-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340946-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","small-molecule-inhibitor-targeting-the-hsp70-bim-proteinprotein-interaction-in-estrogen-receptor-positive-breast-cancer-overcomes-tamoxifen-resistance-research-open-access","Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance - Research Open Access","","Estrogen receptor (ER)-positive breast cancer constitutes about 70% of cases, and tamoxifen is the standard first-line therapy, yet acquired resistance limits its effectiveness. This study uses the Hsp70-Bim protein–protein interaction inhibitor S1g-2 (with related Hsp70-Bag3 and ATP-competitive tools) to probe Hsp70’s role in resistance. Findings show Hsp70-Bim PPI protects ERα36-mediated apoptosis escape, sustaining EGFR expression and reducing tumor growth in vivo by roughly three-fold.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/small-molecule-inhibitor-targeting-the-hsp70-bim-proteinprotein-interaction-in-estrogen-receptor-positive-breast-cancer-overcomes-tamoxifen-resistance-research-open-access/340946/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/small-molecule-inhibitor-targeting-the-hsp70-bim-proteinprotein-interaction-in-estrogen-receptor-positive-breast-cancer-overcomes-tamoxifen-resistance-research-open-access/340946.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why does tamoxifen resistance develop in ER-positive breast cancer?","Question",{"text":63,"@type":64},"The efficacy of tamoxifen is limited by acquired resistance. Reported mechanisms include escape pathways involving receptor tyrosine kinases like EGFR and its downstream signaling, alongside the induction of ERα36-related programs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is S1g-2 and how was it used in this study?",{"text":68,"@type":64},"S1g-2 is a specific inhibitor targeting the Hsp70-Bim protein–protein interaction. It was used alongside additional chemical inhibitors to investigate how Hsp70 contributes to tamoxifen resistance using assays such as viability testing, co-immunoprecipitation, and gene knockdown.",{"name":70,"@type":61,"acceptedAnswer":71},"How does disrupting Hsp70-Bim affect ER signaling and tumor growth?",{"text":72,"@type":64},"Disruption of Hsp70-Bim PPI downregulates ERα36, shifts the survival/apoptosis balance, and is associated with sustained EGFR expression being reduced. In a xenograft model, S1g-2 treatment led to about a three-fold reduction in tumor volume.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340946,1790194733,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Song et al. Breast Cancer Research (2024) 26:33 [https://doi.org/10.1186/s13058-024-01790-0](https://doi.org/10.1186/s13058-024-01790-0)  \nBreast Cancer Research  \n RESEARCH Open Access  \nSmall molecule inhibitor targeting    \nthe Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance  \nTing Song1*, Hong Zhang1, Qicheng Zhao2, Zhiyuan Hu3, Ziqian Wang1, Yang Song4 and Zhichao Zhang1*  \nAbstract  \nIntroduction Estrogen receptor (ER) positive patients compromise about 70% of breast cancers. Tamoxifen, an antagonist of ERα66 (the classic ER), is the most effective and the standard first-line drug. However, its efficacy is limited by the development of acquired resistance.  \nMethods A specific inhibitor of Hsp70-Bim protein–protein interaction (PPI), S1g-2, together with an inhibitor of Hsp70-Bag3 PPI, MKT-077 and an ATP-competitive inhibitor VER155008, were used as chemical tools. Cell viability assays, co-immunoprecipitation and gene knockdown were used to investigate the role of Hsp70 in tamoxifen resistance. A xenograft model was established in which tamoxifen-resistant breast cancer (MCF-7/TAM-R) cells maintained in the presence of 5 μM tamoxifen were subcutaneously inoculated. The anti-tumor efficiency of S1g-2 was measured after a daily injection of 0.8 mg/kg for 14 days.  \nResults It was revealed that Hsp70-Bim PPI protects ERα-positive breast cancer from tamoxifen-induced apoptosis through binding and stabilizing ERα36, rather than ERα66, resulting in sustained EGFR mRNA and protein expression. Disruption of Hsp70-Bim PPI and downregulation of ERα36 expression in tumor samples are consistent with the in vitro functions of S1g-2, resulting in about a three-fold reduction in tumor volume.  \nConclusions The in vivo activity and safety of S1g-2 illustrated that it is a potential strategy for Hsp70-Bim disruption to overcome tamoxifen-resistant ER-positive breast cancer.  \nKeywords Hsp70-Bim PPI, Hsp70-Bag3 PPI, Tamoxifen resistance, Estrogen receptor α36 (ERα36), S1g-2  \n*Correspondence: Ting Song [songting@dlut.edu.cn](songting@dlut.edu.cn)[ ](songting@dlut.edu.cn)Zhichao Zhang [zczhang@dlut.edu.cn](zczhang@dlut.edu.cn)  \n1 Cancer Hospital of Dalian University of Technology, School of Chemistry, Dalian University of Technology, Dalian, Liaoning, China  \n2 Cancer Rehabilitation Center, Shanghai YangZhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tong Ji University, Shanghai, China  \n3 School of Life Science and Technology, Dalian University of Technology, Dalian, Liaoning, China  \n4 Central Hospital of Dalian University of Technology, Dalian, Liaoning, China  \nIntroduction  \nBreast cancer is a leading cause of cancer-related deaths in women worldwide. About 75% of breast cancers are estrogen receptor (ER) positive [1]. Tamoxifen, an antagonist of ERα66 (the classic estrogen receptor), is the most effective drug and has become the standard first-line therapy for women with ER-positive breast cancer [2]. However, its efficacy is limited by the development of acquired tamoxifen resistance. It has been reported that 20% of all ER-positive breast cancer recur with resistance to tamoxifen, leading to more aggressive neoplasms  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use,","cbCainJMyPK3FGV5","https://ap.wps.com/l/cbCainJMyPK3FGV5","pdf",2006984,13,"English","# Introduction\n## Tamoxifen resistance in ER-positive breast cancer\n## ERα36, EGFR, and escape pathways\n# Methods\n## Chemical inhibitors and chemical tools\n## Cell viability, co-immunoprecipitation, gene knockdown\n## Xenograft model and dosing regimen\n# Results\n## Hsp70-Bim PPI sustains ERα36 and EGFR expression\n## Tumor volume reduction in vivo\n# Conclusions","[{\"question\":\"Why does tamoxifen resistance develop in ER-positive breast cancer?\",\"answer\":\"The efficacy of tamoxifen is limited by acquired resistance. Reported mechanisms include escape pathways involving receptor tyrosine kinases like EGFR and its downstream signaling, alongside the induction of ERα36-related programs.\"},{\"question\":\"What is S1g-2 and how was it used in this study?\",\"answer\":\"S1g-2 is a specific inhibitor targeting the Hsp70-Bim protein–protein interaction. It was used alongside additional chemical inhibitors to investigate how Hsp70 contributes to tamoxifen resistance using assays such as viability testing, co-immunoprecipitation, and gene knockdown.\"},{\"question\":\"How does disrupting Hsp70-Bim affect ER signaling and tumor growth?\",\"answer\":\"Disruption of Hsp70-Bim PPI downregulates ERα36, shifts the survival/apoptosis balance, and is associated with sustained EGFR expression being reduced. In a xenograft model, S1g-2 treatment led to about a three-fold reduction in tumor volume.\"}]","Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance - Research Open Access | PDF",1790039651,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b15fc9f1ebdc638dfe79d2121c47f6e7.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6561bc48f4c6840e56ff9910604ecfa.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/395eb342e88901719e07b5079a14036e.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/106b9619189766408bdb920e1bd436d6.webp",980,1301]